Schneider, Jaime L. http://orcid.org/0000-0003-2591-2279
Lin, Jessica J. http://orcid.org/0000-0001-7373-3916
Shaw, Alice T. http://orcid.org/0000-0001-6337-1093
Funding for this research was provided by:
A Breath of Hope Lung Foundation (2022-A004365)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5R01CA164273)
Article History
Received: 3 March 2022
Accepted: 10 January 2023
First Online: 16 February 2023
Competing interests
: J.L.S. has received honoraria from the Academy of Continued Healthcare Learning, Springer Healthcare and Targeted Oncology. J.J.L. has served as a compensated consultant for Genentech, Regeneron, C4 Therapeutics, Blueprint Medicines, Nuvalent, Bayer, Elevation Oncology, Novartis, Mirati Therapeutics and Turning Point Therapeutics; received honorarium and travel support from Pfizer; received institutional research funds from Hengrui Therapeutics, Turning Point Therapeutics, Neon Therapeutics, Relay Therapeutics, Bayer, Elevation Oncology, Roche, Linnaeus Therapeutics, Nuvalent and Novartis; and received CME funding from OncLive, MedStar Health and Northwell Health. A.T.S. is currently employed by Novartis.